Dec 08, 2015 7:00 AM

VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study

Nov 30, 2015 7:00 AM

VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles

Nov 19, 2015 7:00 AM

VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy

Nov 17, 2015 9:00 AM

VolitionRx Granted Its Second U.S. Patent

Nov 12, 2015 7:00 AM

VolitionRx to Present at Two Conferences in November

Nov 04, 2015 6:30 AM

VolitionRx Announces Third Quarter 2015 Financial Results and Business Update

Oct 30, 2015 7:00 AM

VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET

Oct 22, 2015 8:00 AM

VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study

Oct 12, 2015 8:00 AM

VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics

Sep 22, 2015 8:00 AM

VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer

Sep 10, 2015 8:00 AM

VolitionRx Granted Its First U.S. Patent

Sep 09, 2015 9:00 AM

VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial

Sep 02, 2015 9:00 AM

VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015

Sep 01, 2015 9:00 AM

VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015

Aug 17, 2015 9:00 AM

VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer

Aug 11, 2015 7:30 AM

VolitionRx Announces Second Quarter 2015 Financial Results and Business Update

Aug 05, 2015 9:00 AM

VolitionRx Schedules Second Quarter 2015 Earnings Conference Call and Business Update for Tuesday, August 11, 2015 at 8:30am ET

Aug 03, 2015 9:00 AM

VolitionRx to Present at Wedbush PacGrow Healthcare Conference

Jul 27, 2015 9:00 AM

VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs

Jul 08, 2015 9:00 AM

VolitionRx CSO Dr. Jake Micallef to Present Scientific Webinar

Jul 06, 2015 9:18 AM

VolitionRx Expands Scientific Advisory Board

Jun 23, 2015 9:00 AM

VolitionRx Partners with Two Market Access Consulting Agencies to Support Market Access of NuQ(R) Colorectal Cancer Tests in Europe

May 19, 2015 9:00 AM

VolitionRx to Present at Two Upcoming Investor Conferences

May 18, 2015 9:00 AM

VolitionRx CEO Cameron Reynolds to Present Informational Webinar

May 12, 2015 8:50 AM

VolitionRx Announces First Quarter 2015 Financial Results and Business Update

May 08, 2015 9:00 AM

VolitionRx Accelerates Clinical Trial with University Hospital Bonn, Germany Evaluating NuQ® Assays in Most Prevalent Cancers

May 06, 2015 9:00 AM

VolitionRx Schedules First Quarter 2015 Earnings Conference Call and Business Update for Tuesday, May 12, 2015 at 8:30 a.m. ET

Apr 21, 2015 9:00 AM

VolitionRx Initiates Study with Hvidovre Hospital, Denmark, Specifically to Target NuQ(R) Biomarker Panel for Colorectal Polyps

Apr 09, 2015 9:00 AM

VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials

Mar 05, 2015 8:00 AM

VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology

Feb 24, 2015 8:00 AM

VolitionRx Acquires Direct Ownership of Nucleosomics® Technology Patent

Feb 17, 2015 8:00 AM

VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering

Feb 06, 2015 8:00 AM

VolitionRx Limited Prices Public Offering of Common Stock

Jan 20, 2015 5:00 PM

VolitionRx Begins First Ovarian Cancer Detection Study

Jan 07, 2015 8:00 AM

Press Releases